Oragenics Inc (OGEN) Short Interest Up 155.3% in December

Oragenics Inc (NYSEAMERICAN:OGEN) was the target of a significant growth in short interest in December. As of December 29th, there was short interest totalling 286,908 shares, a growth of 155.3% from the December 15th total of 112,379 shares. Based on an average daily trading volume, of 352,168 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.8% of the company’s shares are sold short.

Separately, ValuEngine raised Oragenics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 26th.

Shares of Oragenics (NYSEAMERICAN OGEN) opened at $0.17 on Monday. Oragenics has a one year low of $0.06 and a one year high of $0.85. The firm has a market capitalization of $8.38, a price-to-earnings ratio of -1.06 and a beta of 1.32.

Shares of Oragenics are scheduled to reverse split on Monday, January 22nd. The 1-10 reverse split was announced on Monday, January 8th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 19th.

TRADEMARK VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/15/oragenics-inc-ogen-short-interest-up-155-3-in-december.html.

Oragenics Company Profile

Oragenics, Inc develops, markets and sells probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora. The Company is focused on offering antibiotics against infectious disease and on developing treatments for oral mucositis. It is engaged in developing its antibiotic product candidate, MU1140, as well as other homolog antibiotic product candidates; researching AG013 in connection with the treatment of Oral Mucositis; commercializing its ProBiora3 probiotic products, and has other product candidates for out licensing or partnering.

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply